Cell cycle arrest in Batten disease lymphoblast cells

Gene

Volumn 519, Issue 2, 2013, Pages 245-250

  Kang, Sunyang ^a   Kim, June Bum ^b   Heo, Tae Hwe ^c   Kim, Sung Jo ^a  

^a Hoseo University   (South Korea)

^b Seoul Children's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Batten disease; Cell cycle arrest; Glucosylceramide; P21; Sphingosine; Sulfatide

Indexed keywords

CEROID LIPOFUSCINOSIS NEURONAL 3 PROTEIN; GLUCOSYLCERAMIDE; MEMBRANE PROTEIN; PROTEIN P21; SPHINGOSINE; SULFATIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LYMPHOBLAST; NEURONAL CEROID LIPOFUSCINOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GLUCOSYLCERAMIDES; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR CHAPERONES; NEURONAL CEROID-LIPOFUSCINOSES; SPHINGOLIPIDS; SPHINGOSINE; SULFOGLYCOSPHINGOLIPIDS; UP-REGULATION;

EID: 84875619492     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.02.022     Document Type: Article

References (38)

1. Benedict J.W., Sommers C.A., Pearce D.A. Progressive oxidative damage in the central nervous system of a murine model for juvenile Batten disease. J. Neurosci. Res. 2007, 85:2882-2891.
2. Brady R.O., Kanfer J.N., Bradley R.M., Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 1966, 45:1112-1115.
3. Consortium T.I.B.D. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 1995, 82:949-957.
4. Dulić V., Beney G.E., Frebourg G., Drullinger L.F., Stein G.H. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts. Mol. Cell. Biol. 2000, 20:6741-6754.
5. Eckhardt M., et al. Sulfatide storage in neurons causes hyperexcitability and axonal degeneration in a mouse model of metachromatic leukodystrophy. J. Neurosci. 2007, 27:9009-9021.
6. Fujiwara K., et al. Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy. J. Biol. Chem. 2008, 283:388.
7. Fuller M. Sphingolipids: the nexus between Gaucher disease and insulin resistance. Lipids Health Dis. 2010, 9:113.
8. Gartel A.L. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk. Res. 2005, 29:1237-1238.
9. Guo W.-X., Mao C., Obeid L.M., Boustany R.-M. A disrupted homologue of the human CLN3 or juvenile neuronal ceroid lipofuscinosis gene in Saccharomyces cerevisiae: a model to study Batten disease. Cell. Mol. Neurobiol. 1999, 19(5):671-680.
10. Hait N.C., et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
11. Haltia M. The neuronal ceroid-lipofuscinoses. J. Neuropathol. Exp. Neurol. 2003, 62:1-13.
12. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
13. Huang J.Q., Trasler J.M., Igdoura S., Michaud J., Hanal N., Gravel R.A. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 1997, 6:1879-1885.
14. Jung Y.-S., Qian Y., Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell. Signal. 2010, 22:1003-1012.
15. Kang K.H., Kim W.H., Choi K.H. p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp. Cell. Res. 1999, 253:403-412.
16. Kielar C., et al. Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease. Hum. Mol. Genet. 2009, 18:4066-4080.
17. Kim J.-B., Lim N., Kim S.-J., Heo T.-H. N-acetylcysteine normalizes the urea cycle and DNA repair in cells from patients with Batten disease. Cell Biochem. Funct. 2012, 30:677-682.
18. Kitamura S., Miyazaki Y., Shinomura Y., Kondo S., Kanayama S., Matsuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res. 1999, 90:75-80.
19. Korkotian E., Schwarz A., Pelled D., Schwarzmann G., Segal M., Futerman A.H. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 1999, 274:21673-21678.
20. Lincet H., et al. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett. 2000, 161:17-26.
21. Luberto C., Kraveka J.M., Hannun Y.A. Ceramide regulation of apoptosis versus differentiation: a walk on a fine line. Lessons from neurobiology. Neurochem. Res. 2002, 27:609-617.
22. Lucki N.C., Sewer M.B. Nuclear sphingolipid metabolism. Annu. Rev. Physiol. 2012, 74:131-151.
23. Luiro K. Molecular and cellular mechanisms behind juvenile neuronal ceroid lipofuscinosis (JNCL, Batten Disease) 2006, Series A of the publications of the National Public Health Institute.
24. Mitchison H.M., Mole S.E. Neurodegenerative disease: the neuronal ceroid lipofuscinoses (Batten disease). Curr. Opin. Neurol. 2001, 14:795-803.
25. Nugent T., Mole S.E., Jones D.T. The transmembrane topology of Batten disease protein CLN3 determined by consensus computational prediction constrained by experimental data. FEBS Lett. 2008, 582:1019-1024.
26. Osório N.S., et al. Nitric oxide signaling is disrupted in the yeast model for Batten disease. Mol. Biol. Cell 2007, 18:2755-2767.
27. Persaud-Sawin D.A., Boustany R.-M.N. Cell death pathways in juvenile Batten disease. Apoptosis 2005, 10:973-985.
28. Phillips S.N., Benedict J.W., Weimer J.M., Pearce D.A. CLN3, the protein associated with batten disease: structure, function and localization. J. Neurosci. Res. 2005, 79:573-583.
29. Puranam K.L., Guo W.X., Qian W.H., Nikbakht K., Boustany R.M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol. Genet. Metab. 1999, 66:294-308.
30. Qiao L., et al. Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology 2002, 36:39-48.
31. Rusyn E., Mousallem T., Persaud-Sawin D.-A., Miller S., Boustany R.-M.N. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content. Pediatr. Res. 2008, 63:625-631.
32. Ségui B., Andrieu-Abadie N., Jaffrézou J.-P., Benoist H., Levade T. Sphingolipids as modulators of cancer cell death: potential therapeutic targets. Biochim. Biophys. Acta 2006, 1758:2104-2120.
33. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 2003, 4:397-407.
34. Tuxworth R.I., Chen H., Vivancos V., Carvajal N., Huang X., Tear G. The Batten disease gene CLN3 is required for the response to oxidative stress. Hum. Mol. Genet. 2011, 20:2037-2047.
35. Vermeulen K., Berneman Z.N., Van Bockstaele D.R. Cell cycle and apoptosis. Cell Prolif. 2003, 36:165-175.
36. Wei H., Kim S.J., Zhang Z., Tsai P.C., Wisniewski K.E., Mukherjee A.B. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet. 2007, 17:469-477.
37. Wisniewski K.E., Zhong N., Philippart M. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology 2001, 57:576-581.
38. Zeng Y., Cheng H., Jiang X., Han X. Endosomes and lysosomes play distinct roles in sulfatide-induced neuroblastoma apoptosis: potential mechanisms contributing to abnormal sulfatide metabolism in related neuronal diseases. Biochem. J. 2008, 410:81.